Samsung Bioepis has submitted a biosimilar version of Roche's breast cancer blockbuster Herceptin in the EU, hard on the heels of rivals Biocon and Mylan.

Merck’s Keytruda could become a national tourist attraction in China, with a special approval for imports to the resort island of Hainan.

With forced price cuts for brands such as Gilead Sciences' hep C med Sovaldi already under its belt, the Japanese government is weighing others to help…

Hepatitis C is a big problem in China, and drugmakers are still waiting on approval for their next-gen treatments. Now, regulators are promising action--and…

Government warns drugmakers could leave the UK if the country's separation from the EU drags on and is kept under wraps.

Mitsubishi Tanabe is hoping to end a 20-year drought in the U.S. for new ALS medicines.

Biocon and partner Mylan have moved one step closer to launching a Herceptin biosimilar in Europe--and they claim they've beaten their rivals to the punch…

Bristol-Myers Squibb partner Ono Pharmaceutical bagged a third approval in Japan for immuno-oncology drug Opdivo, its most important new product.

The Japan leg of a major postmarketing study on Bayer's Xarelto set a milestone in patient numbers.

Regulatory